Although there is a need for detailed functional analyses of OASIS and its related signaling pathways including the transcriptional targets in patients with IBD, OASIS and its downstream molecules might be novel targets for development of therapeutic strategies against human IBD. Here, CREB3L1 is linked to inflammatory bowel disease.